24 results on '"Xue, Jinyu"'
Search Results
2. Predicting local failure of brain metastases after stereotactic radiosurgery with radiomics on planning MR images and dose maps.
- Author
-
Wang H, Xue J, Qu T, Bernstein K, Chen T, Barbee D, Silverman JS, and Kondziolka D
- Subjects
- Humans, Magnetic Resonance Imaging, ROC Curve, Retrospective Studies, Brain Neoplasms diagnostic imaging, Brain Neoplasms radiotherapy, Brain Neoplasms surgery, Radiosurgery
- Abstract
Purpose: Stereotactic radiosurgery (SRS) has become an important modality in the treatment of brain metastases. The purpose of this study is to investigate the potential of radiomic features from planning magnetic resonance (MR) images and dose maps to predict local failure after SRS for brain metastases., Materials/methods: Twenty-eight patients who received Gamma Knife (GK) radiosurgery for brain metastases were retrospectively reviewed in this IRB-approved study. 179 irradiated tumors included 42 that locally failed within one-year follow-up. Using SRS tumor volumes, radiomic features were calculated on T1-weighted contrast-enhanced MR images acquired for treatment planning and planned dose maps. 125 radiomic features regarding tumor shape, dose distribution, MR intensities and textures were extracted for each tumor. Logistic regression with automatic feature selection was built to predict tumor progression from local control after SRS. Feature selection and model evaluation using receiver operating characteristic (ROC) curves were performed in a nested cross validation (CV) scheme. The associations between selected radiomic features and treatment outcomes were statistically assessed by univariate analysis., Results: The logistic model with feature selection achieved ROC AUC of 0.82 ± 0.09 on 5-fold CV, providing 83% sensitivity and 70% specificity for predicting local failure. A total of 10 radiomic features including 1 shape feature, 6 MR images and 3 dose distribution features were selected. These features were significantly associated with treatment outcomes (p < 0.05). The model was validated on independent holdout data with an AUC of 0.78., Conclusions: Radiomic features from planning MR images and dose maps provided prognostic information in SRS for brain metastases. A model built on the radiomic features shows promise for early prediction of tumor local failure after treatment, potentially aiding in personalized care for brain metastases., (© 2021 American Association of Physicists in Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
3. High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview.
- Author
-
Grimm J, Marks LB, Jackson A, Kavanagh BD, Xue J, and Yorke E
- Subjects
- Age Factors, Dose-Response Relationship, Radiation, Humans, Organ Specificity, Organs at Risk radiation effects, Practice Guidelines as Topic, Radiosurgery adverse effects, Radiotherapy Planning, Computer-Assisted, Neoplasms radiotherapy, Radiation Dose Hypofractionation, Radiosurgery methods, Systematic Reviews as Topic
- Published
- 2021
- Full Text
- View/download PDF
4. Initial Data Pooling for Radiation Dose-Volume Tolerance for Carotid Artery Blowout and Other Bleeding Events in Hypofractionated Head and Neck Retreatments.
- Author
-
Grimm J, Vargo JA, Mavroidis P, Moiseenko V, Emami B, Jain S, Caudell JJ, Clump DA, Ling DC, Das S, Moros EG, Vinogradskiy Y, Xue J, and Heron DE
- Subjects
- Carotid Arteries diagnostic imaging, Carotid Artery Injuries etiology, Dose-Response Relationship, Radiation, Head and Neck Neoplasms diagnostic imaging, Humans, Logistic Models, Models, Biological, Models, Theoretical, Radiation Dose Hypofractionation, Radiation Injuries complications, Spinal Cord radiation effects, Carotid Arteries radiation effects, Carotid Artery Diseases etiology, Hemorrhage etiology, Radiation Tolerance, Radiosurgery adverse effects, Re-Irradiation adverse effects
- Abstract
Purpose: Dose-volume data for injury to carotid artery and other major vessels in stereotactic body radiation therapy (SBRT)/SABR head and neck reirradiation were reviewed, modeled, and summarized., Methods and Materials: A PubMed search of the English-language literature (stereotactic and carotid and radiation) in April 2018 found 238 major vessel maximum point doses in 6 articles that were pooled for logistic modeling. Two subsequent studies with dose-volume major vessel data were modeled separately for comparison. Attempts were made to separate carotid blowout syndrome from other bleeding events (BE) in the analysis, but we acknowledge that all except 1 data set has some element of BE interspersed., Results: Prior radiation therapy (RT) dose was not uniformly reported per patient in the studies included, but a course on the order of conventionally fractionated 70 Gy was considered for the purposes of the analysis (with an approximately ≥6-month estimated interval between prior and subsequent treatment in most cases). Factors likely associated with reduced risk of BE include nonconsecutive daily treatment, lower extent of circumferential tumor involvement around the vessel, and no surgical manipulation before or after SBRT., Conclusions: Initial data pooling for reirradiation involving the carotid artery resulted in 3 preliminary models compared in this Hypofractionated Treatment Effects in the Clinic (HyTEC) report. More recent experiences with alternating fractionation schedules and additional risk-reduction strategies are also presented. Complications data for the most critical structures such as spinal cord and carotid artery are so limited that they cannot be viewed as strong conclusions of probability of risk, but rather, as a general guideline for consideration. There is a great need for better reporting standards as noted in the High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic introductory paper., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
5. Stereotactic Body Radiation Therapy for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards.
- Author
-
Soltys SG, Grimm J, Milano MT, Xue J, Sahgal A, Yorke E, Yamada Y, Ding GX, Li XA, Lovelock DM, Jackson A, Ma L, El Naqa I, Gibbs IC, Marks LB, and Benedict S
- Subjects
- Cancer Pain radiotherapy, Dose-Response Relationship, Radiation, Humans, Logistic Models, Models, Biological, Models, Theoretical, Probability, Radiation Dose Hypofractionation, Radiosurgery standards, Radiotherapy Dosage, Spinal Neoplasms diagnostic imaging, Spinal Neoplasms pathology, Treatment Outcome, Tumor Burden, Radiosurgery methods, Spinal Neoplasms radiotherapy, Spinal Neoplasms secondary
- Abstract
Purpose: We sought to investigate the tumor control probability (TCP) of spinal metastases treated with stereotactic body radiation therapy (SBRT) in 1 to 5 fractions., Methods and Materials: PubMed-indexed articles from 1995 to 2018 were eligible for data extraction if they contained SBRT dosimetric details correlated with actuarial 2-year local tumor control rates. Logistic dose-response models of collected data were compared in terms of physical dose and 3-fraction equivalent dose., Results: Data were extracted from 24 articles with 2619 spinal metastases. Physical dose TCP modeling of 2-year local tumor control from the single-fraction data were compared with data from 2 to 5 fractions, resulting in an estimated α/β = 6 Gy, and this was used to pool data. Acknowledging the uncertainty intrinsic to the data extraction and modeling process, the 90% TCP corresponded to 20 Gy in 1 fraction, 28 Gy in 2 fractions, 33 Gy in 3 fractions, and (with extrapolation) 40 Gy in 5 fractions. The estimated TCP for common fractionation schemes was 82% at 18 Gy, 90% for 20 Gy, and 96% for 24 Gy in a single fraction, 82% for 24 Gy in 2 fractions, and 78% for 27 Gy in 3 fractions., Conclusions: Spinal SBRT with the most common fractionation schemes yields 2-year estimates of local control of 82% to 96%. Given the heterogeneity in the tumor control estimates extracted from the literature, with variability in reporting of dosimetry data and the definition of and statistical methods of reporting tumor control, care should be taken interpreting the resultant model-based estimates. Depending on the clinical intent, the improved TCP with higher dose regimens should be weighed against the potential risks for greater toxicity. We encourage future reports to provide full dosimetric data correlated with tumor local control to allow future efforts of modeling pooled data., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
6. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases.
- Author
-
Redmond KJ, Gui C, Benedict S, Milano MT, Grimm J, Vargo JA, Soltys SG, Yorke E, Jackson A, El Naqa I, Marks LB, Xue J, Heron DE, and Kleinberg LR
- Subjects
- Brain pathology, Brain radiation effects, Brain Neoplasms pathology, Disease Progression, Humans, Melanoma pathology, Melanoma radiotherapy, Melanoma secondary, Models, Biological, Models, Theoretical, Necrosis, Probability, Radiation Dose Hypofractionation, Radiosurgery instrumentation, Treatment Outcome, Tumor Burden, Brain Neoplasms radiotherapy, Brain Neoplasms secondary, Radiosurgery methods
- Abstract
Purpose: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, tumor control probability (TCP) after stereotactic radiosurgery (SRS) and fractionated stereotactic radiosurgery (fSRS) for brain metastases was modeled based on pooled dosimetric and clinical data from published English-language literature., Methods and Materials: PubMed-indexed studies published between January 1995 and September 2017 were used to evaluate dosimetric and clinical predictors of TCP after SRS or fSRS for brain metastases. Eligible studies had ≥10 patients and included detailed dose-fractionation data with corresponding ≥1-year local control (LC) data, typically evaluated as a >20% increase in diameter of the targeted lesion using the pre-SRS diameter as a reference., Results: Of 2951 potentially eligible manuscripts, 56 included sufficient dose-volume data for analyses. Accepting that necrosis and pseudoprogression can complicate the assessment of LC, for tumors ≤20 mm, single-fraction doses of 18 and 24 Gy corresponded with >85% and 95% 1-year LC rates, respectively. For tumors 21 to 30 mm, an 18 Gy single-fraction dose was associated with 75% LC. For tumors 31 to 40 mm, a 15 Gy single-fraction dose yielded ∼69% LC. For 3- to 5-fraction fSRS using doses in the range of 27 to 35 Gy, 80% 1-year LC has been achieved for tumors of 21 to 40 mm in diameter., Conclusions: TCP for SRS and fSRS are presented. For small lesions ≤20 mm, single doses of ≈18 Gy appear generally associated with excellent rates of LC; for melanoma, higher doses seem warranted. For larger lesions >20 mm, local control rates appear to be ≈ 70% to 75% with usual doses of 15 to 18 Gy, and in this setting, fSRS regimens should be considered. Greater consistency in reporting of dosimetric and LC data is needed to facilitate future pooled analyses. As systemic and biologic therapies evolve, updated analyses will be needed to further assess the necessity, efficacy, and toxicity of SRS and fSRS., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
7. Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways.
- Author
-
Milano MT, Grimm J, Soltys SG, Yorke E, Moiseenko V, Tomé WA, Sahgal A, Xue J, Ma L, Solberg TD, Kirkpatrick JP, Constine LS, Flickinger JC, Marks LB, and El Naqa I
- Subjects
- Adenoma radiotherapy, Blindness etiology, Cavernous Sinus, Craniopharyngioma radiotherapy, Humans, Maximum Tolerated Dose, Meningeal Neoplasms radiotherapy, Meningioma radiotherapy, Models, Biological, Models, Theoretical, Optic Chiasm radiation effects, Pituitary Neoplasms radiotherapy, Radiation Dose Hypofractionation, Radiation Tolerance, Radiosurgery methods, Radiotherapy Dosage, Re-Irradiation, Skull Base Neoplasms radiotherapy, Visual Acuity radiation effects, Visual Fields radiation effects, Optic Nerve radiation effects, Organs at Risk radiation effects, Radiosurgery adverse effects
- Abstract
Purpose: Dosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation., Methods and Materials: Eligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION)., Results: Thirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in <1% RION risks include 12 Gy in 1 fraction (which is greater than our recommendation of 10 Gy in 1 fraction), 20 Gy in 3 fractions, and 25 Gy in 5 fractions. Omitting multi-fraction data (and thereby eliminating uncertainties associated with dose conversions), a single-fraction dose of 10 Gy was associated with a 1% RION risk. Insufficient details precluded modeling of NTCP risks after prior radiation therapy., Conclusions: Optic apparatus NTCP and tolerance doses after single- and multi-fraction stereotactic radiosurgery are presented. Additional standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses and better define RION NTCP after SRS/fSRS., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
8. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.
- Author
-
Milano MT, Grimm J, Niemierko A, Soltys SG, Moiseenko V, Redmond KJ, Yorke E, Sahgal A, Xue J, Mahadevan A, Muacevic A, Marks LB, and Kleinberg LR
- Subjects
- Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Brain pathology, Brain Edema etiology, Brain Neoplasms secondary, Brain Neoplasms surgery, Brain Stem radiation effects, Disease Progression, Humans, Immune Checkpoint Inhibitors therapeutic use, Models, Biological, Models, Theoretical, Necrosis diagnosis, Necrosis etiology, Necrosis pathology, Organs at Risk pathology, Probability, Radiation Dose Hypofractionation, Radiation Injuries diagnosis, Radiation Injuries pathology, Radiation Tolerance, Radiosurgery methods, Radiotherapy Dosage, Re-Irradiation, Brain radiation effects, Brain Neoplasms radiotherapy, Intracranial Arteriovenous Malformations radiotherapy, Organs at Risk radiation effects, Radiation Injuries etiology, Radiosurgery adverse effects
- Abstract
Purpose: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS)., Methods and Materials: Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases., Results: Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm
3 , 10 cm3 , or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection., Conclusions: The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks., (Copyright © 2020 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
9. Stereotactic Radiosurgery for Vestibular Schwannomas: Tumor Control Probability Analyses and Recommended Reporting Standards.
- Author
-
Soltys SG, Milano MT, Xue J, Tomé WA, Yorke E, Sheehan J, Ding GX, Kirkpatrick JP, Ma L, Sahgal A, Solberg T, Adler J, Grimm J, and El Naqa I
- Subjects
- Dose Fractionation, Radiation, Humans, Linear Models, Models, Biological, Models, Theoretical, Neurofibromatosis 2 therapy, Poisson Distribution, Probability, Radiosurgery standards, Radiotherapy Dosage, Relative Biological Effectiveness, Time Factors, Treatment Outcome, Neuroma, Acoustic radiotherapy, Radiosurgery methods
- Abstract
Purpose: We sought to investigate the tumor control probability (TCP) of vestibular schwannomas after single-fraction stereotactic radiosurgery (SRS) or hypofractionated SRS over 2 to 5 fractions (fSRS)., Methods and Materials: Studies (PubMed indexed from 1993-2017) were eligible for data extraction if they contained dosimetric details of SRS/fSRS correlated with local tumor control. The rate of tumor control at 5 years (or at 3 years if 5-year data were not available) were collated. Poisson modeling estimated the TCP per equivalent dose in 2 Gy per fraction (EQD2) and in 1, 3, and 5 fractions., Results: Data were extracted from 35 publications containing a total of 5162 patients. TCP modeling was limited by the absence of analyzable data of <11 Gy in a single-fraction, variability in definition of "tumor control," and by lack of significant increase in TCP for doses >12 Gy. Using linear-quadratic-based dose conversion, the 3- to 5-year TCP was estimated at 95% at an EQD2 of 25 Gy, corresponding to 1-, 3-, and 5-fraction doses of 13.8 Gy, 19.2 Gy, and 21.5 Gy, respectively. Single-fraction doses of 10 Gy, 11 Gy, 12 Gy, and 13 Gy predicted a TCP of 85.0%, 88.4%, 91.2%, and 93.5%, respectively. For fSRS, 18 Gy in 3 fractions (EQD2 of 23.0 Gy) and 25 Gy in 5 fractions (EQD2 of 30.2 Gy) corresponded to TCP of 93.6% and 97.2%. Overall, the quality of dosimetric reporting was poor; recommended reporting guidelines are presented., Conclusions: With current typical SRS doses of 12 Gy in 1 fraction, 18 Gy in 3 fractions, and 25 Gy in 5 fractions, 3- to 5-year TCP exceeds 91%. To improve pooled data analyses to optimize treatment outcomes for patients with vestibular schwannoma, future reports of SRS should include complete dosimetric details with well-defined tumor control and toxicity endpoints., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
10. Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.
- Author
-
Zhao J, Yorke ED, Li L, Kavanagh BD, Li XA, Das S, Miften M, Rimner A, Campbell J, Xue J, Jackson A, Grimm J, Milano MT, and Spring Kong FM
- Subjects
- Age Distribution, Aged, Aged, 80 and over, Causality, Comorbidity, Dose-Response Relationship, Radiation, Female, Humans, Incidence, Lung Neoplasms diagnosis, Male, Middle Aged, Radiation Pneumonitis diagnosis, Radiotherapy Dosage, Reproducibility of Results, Risk Factors, Sensitivity and Specificity, Treatment Outcome, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms epidemiology, Lung Neoplasms radiotherapy, Radiation Pneumonitis epidemiology, Radiosurgery statistics & numerical data
- Abstract
Purpose: To study the risk factors for radiation-induced lung toxicity (RILT) after stereotactic body radiation therapy (SBRT) of the thorax., Methods and Materials: Published studies on lung toxicity in patients with early-stage non-small cell lung cancer (NSCLC) or metastatic lung tumors treated with SBRT were pooled and analyzed. The primary endpoint was RILT, including pneumonitis and fibrosis. Data of RILT and risk factors were extracted from each study, and rates of grade 2 to 5 (G2+) and grade 3 to 5 (G3+) RILT were computed. Patient, tumor, and dosimetric factors were analyzed for their correlation with RILT., Results: Eighty-eight studies (7752 patients) that reported RILT incidence were eligible. The pooled rates of G2+ and G3+ RILT from all 88 studies were 9.1% (95% confidence interval [CI]: 7.15-11.4) and 1.8% (95% CI: 1.3-2.5), respectively. The median of median tumor sizes was 2.3 (range, 1.4-4.1) cm. Among the factors analyzed, older patient age (P=.044) and larger tumor size (the greatest diameter) were significantly correlated with higher rates of G2+ (P=.049) and G3+ RILT (P=.001). Patients with stage IA versus stage IB NSCLC had significantly lower risks of G2+ RILT (8.3% vs 17.1%, odds ratio = 0.43, 95% CI: 0.29-0.64, P<.0001). Among studies that provided detailed dosimetric data, the pooled analysis demonstrated a significantly higher mean lung dose (MLD) (P=.027) and V20 (P=.019) in patients with G2+ RILT than in those with grade 0 to 1 RILT., Conclusions: The overall rate of RILT is relatively low after thoracic SBRT. Older age and larger tumor size are significant adverse risk factors for RILT. Lung dosimetry, specifically lung V20 and MLD, also significantly affect RILT risk., (Copyright © 2016. Published by Elsevier Inc.)
- Published
- 2016
- Full Text
- View/download PDF
11. Stereotactic Radiosurgery for Poor Performance Status Patients.
- Author
-
Kubicek GJ, Turtz A, Xue J, Patel A, Richards G, LaCouture T, Cappelli L, Diestelkamp T, Saraiya P, Bexon A, Lerman N, and Goldman HW
- Subjects
- Aged, Aged, 80 and over, Brain Neoplasms psychology, Cranial Irradiation statistics & numerical data, Female, Humans, Male, Middle Aged, Radiosurgery statistics & numerical data, Retrospective Studies, Survival Rate, Treatment Failure, Treatment Outcome, Activities of Daily Living psychology, Brain Neoplasms mortality, Brain Neoplasms radiotherapy, Cranial Irradiation mortality, Radiosurgery mortality
- Abstract
Purpose: Patients with poor performance status (PS), usually defined as a Karnofsky Performance Status of 60 or less, were not eligible for randomized stereotactic radiosurgery (SRS) studies, and many guidelines suggest that whole-brain radiation therapy (WBRT) is the most appropriate treatment for poor PS patients., Methods and Materials: In this retrospective review of our SRS database, we identified 36 patients with PS of 60 or less treated with SRS for central nervous system (CNS) metastatic disease. PS, as defined by the Karnofsky Performance Status, was 60 (27 patients), 50 (8 patients), or 40 (1 patient). The median number of CNS lesions treated was 3., Results: Median overall survival (OS) was 7.2 months (range, 0.73-25.6 months). Fifteen patients (41%) were alive at 6 months, and 6 patients (16.6%) were alive at 1 year. There was no difference in OS in patients who underwent previous WBRT. There were no local failures or cases of radiation toxicity. Distant CNS failures were seen in 9 patients (25%)., Conclusions: Our patients with poor PS had reasonable median OS and relatively low distant CNS failure rates. Patients in this patient population may be ideal candidates for SRS compared with WBRT given the low incidence of distant failure over their remaining lives and the favorable logistics of single-fraction treatment for these patients with debility and their caregivers., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
12. Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord.
- Author
-
Grimm J, Sahgal A, Soltys SG, Luxton G, Patel A, Herbert S, Xue J, Ma L, Yorke E, Adler JR, and Gibbs IC
- Subjects
- Humans, Radiation Injuries prevention & control, Radiotherapy Dosage, Risk, Radiation Tolerance, Radiosurgery methods, Spinal Cord radiation effects
- Abstract
A literature review of more than 200 stereotactic body radiation therapy spine articles from the past 20 years found only a single article that provided dose-volume data and outcomes for each spinal cord of a clinical dataset: the Gibbs 2007 article (Gibbs et al, 2007(1)), which essentially contains the first 100 stereotactic body radiation therapy (SBRT) spine treatments from Stanford University Medical Center. The dataset is modeled and compared in detail to the rest of the literature review, which found 59 dose tolerance limits for the spinal cord in 1-5 fractions. We partitioned these limits into a unified format of high-risk and low-risk dose tolerance limits. To estimate the corresponding risk level of each limit we used the Gibbs 2007 clinical spinal cord dose-volume data for 102 spinal metastases in 74 patients treated by spinal radiosurgery. In all, 50 of the patients were previously irradiated to a median dose of 40Gy in 2-3Gy fractions and 3 patients developed treatment-related myelopathy. These dose-volume data were digitized into the dose-volume histogram (DVH) Evaluator software tool where parameters of the probit dose-response model were fitted using the maximum likelihood approach (Jackson et al, 1995(3)). Based on this limited dataset, for de novo cases the unified low-risk dose tolerance limits yielded an estimated risk of spinal cord injury of ≤1% in 1-5 fractions, and the high-risk limits yielded an estimated risk of ≤3%. The QUANTEC Dmax limits of 13Gy in a single fraction and 20Gy in 3 fractions had less than 1% risk estimated from this dataset, so we consider these among the low-risk limits. In the previously irradiated cohort, the estimated risk levels for 10 and 14Gy maximum cord dose limits in 5 fractions are 0.4% and 0.6%, respectively. Longer follow-up and more patients are required to improve the risk estimates and provide more complete validation., Competing Interests: Conflict of Interests Notification: None of the authors has received any funding for this research. Dr. Grimm developed and holds intellectual property rights to the DVH Evaluator software tool which is an FDA-cleared product in commercial use, which has been used for this analysis., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
13. Small Bowel Dose Tolerance for Stereotactic Body Radiation Therapy.
- Author
-
LaCouture TA, Xue J, Subedi G, Xu Q, Lee JT, Kubicek G, and Asbell SO
- Subjects
- Dose Fractionation, Radiation, Humans, Radiation Injuries prevention & control, Intestine, Small radiation effects, Radiation Tolerance, Radiosurgery methods
- Abstract
Inconsistencies permeate the literature regarding small bowel dose tolerance limits for stereotactic body radiation therapy (SBRT) treatments. In this review, we organized these diverse published limits with MD Anderson at Cooper data into a unified framework, constructing the dose-volume histogram (DVH) Risk Map, demonstrating low-risk and high-risk SBRT dose tolerance limits for small bowel. Statistical models of clinical data from 2 institutions were used to assess the safety spectrum of doses used in the exposure of the gastrointestinal tract in SBRT; 30% of the analyzed cases had vascular endothelial growth factor inhibitors (VEGFI) or other biological agents within 2 years before or after SBRT. For every dose tolerance limit in the DVH Risk Map, the probit dose-response model was used to estimate the risk level from our clinical data. Using the current literature, 21Gy to 5cc of small bowel in 3 fractions has low toxicity and is reasonably safe, with 6.5% estimated risk of grade 3 or higher complications, per Common Terminology Criteria for Adverse Events version 4.0. In the same fractionation for the same volume, if lower risk is required, 16.2Gy has an estimated risk of only 2.5%. Other volumes and fractionations are also reviewed; for all analyzed high-risk small bowel limits, the risk is 8.2% or less, and the low-risk limits have 4% or lower estimated risk. The results support current clinical practice, with some possibility for dose escalation., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
14. Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels.
- Author
-
Xue J, Kubicek G, Patel A, Goldsmith B, Asbell SO, and LaCouture TA
- Subjects
- Humans, Radiotherapy Dosage, Reproducibility of Results, Aorta radiation effects, Blood Vessels radiation effects, Radiation Injuries prevention & control, Radiation Tolerance, Radiosurgery methods, Radiotherapy Planning, Computer-Assisted methods
- Abstract
Understanding dose constraints for critical structures in stereotactic body radiation therapy (SBRT) is essential to generate a plan for optimal efficacy and safety. Published dose constraints are derived by a variety of methods, including crude statistics, actuarial analysis, modeling, and simple biologically effective dose (BED) conversion. Many dose constraints reported in the literature are not consistent with each other, secondary to differences in clinical and dosimetric parameters. Application of a dose constraint without discriminating the variation of all the factors involved may result in suboptimal treatment. This issue of Seminars in Radiation Oncology validates dose tolerance limits for 10 critical anatomic structures based on dose response modeling of clinical outcomes data to include detailed dose-volume metrics. This article presents a logistic dose-response model for aorta and major vessels based on 238 cases from the literature in addition to 387 cases from MD Anderson Cancer Center at Cooper University Hospital, for a total of 625 cases. The Radiation Therapy Oncology Group (RTOG) 0813 dose-tolerance limit of Dmax = 52.5Gy in 5 fractions was found to have a 1.2% risk of grade 3-5 toxicity, and the Timmerman 2008 limit of Dmax = 45Gy in 3 fractions had 2.3% risk. From the model, the 1% and 2% risk levels for D4cc, D1cc, and D0.5cc are also provided in 1-5 fractions, in the form of a dose-volume histogram (DVH) Risk Map., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
15. Introduction and Clinical Overview of the DVH Risk Map.
- Author
-
Asbell SO, Grimm J, Xue J, Chew MS, and LaCouture TA
- Subjects
- Dose Fractionation, Radiation, Dose-Response Relationship, Radiation, Humans, Radiation Tolerance, Radiotherapy Dosage, Risk, Radiation Injuries prevention & control, Radiosurgery methods, Radiotherapy Planning, Computer-Assisted methods
- Abstract
Radiation oncologists need reliable estimates of risk for various fractionation schemes for all critical anatomical structures throughout the body, in a clinically convenient format. Reliable estimation theory can become fairly complex, however, and estimates of risk continue to evolve as the literature matures. To navigate through this efficiently, a dose-volume histogram (DVH) Risk Map was created, which provides a comparison of radiation tolerance limits as a function of dose, fractionation, volume, and risk level. The graphical portion of the DVH Risk Map helps clinicians to easily visualize the trends, whereas the tabular portion provides quantitative precision for clinical implementation. The DVH Risk Map for rib tolerance from stereotactic ablative body radiotherapy (SABR) and stereotactic body radiation therapy (SBRT) is used as an example in this overview; the 5% and 50% risk levels for 1-5 fractions for 5 different volumes are given. Other articles throughout this issue of Seminars in Radiation Oncology present analysis of new clinical datasets including the DVH Risk Maps for other anatomical structures throughout the body., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
16. Biological implications of whole-brain radiotherapy versus stereotactic radiosurgery of multiple brain metastases.
- Author
-
Xue J, Kubicek GJ, Grimm J, LaCouture T, Chen Y, Goldman HW, and Yorke E
- Subjects
- Breast Neoplasms pathology, Cranial Irradiation adverse effects, Cranial Irradiation methods, Female, Humans, Male, Radiation Injuries etiology, Radiosurgery adverse effects, Radiotherapy adverse effects, Retrospective Studies, Severity of Illness Index, Brain Neoplasms radiotherapy, Brain Neoplasms secondary, Brain Neoplasms surgery, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung secondary, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms pathology, Radiosurgery methods, Radiotherapy methods, Radiotherapy Dosage
- Abstract
Object: The efficacy and safety of treatment with whole-brain radiotherapy (WBRT) or with stereotactic radiosurgery (SRS) for multiple brain metastases (> 10) are topics of ongoing debate. This study presents detailed dosimetric and biological information to investigate the possible clinical outcomes of these 2 modalities., Methods: Five patients with multiple brain metastases (n = 11-23) underwent SRS. Whole-brain radiotherapy plans were retrospectively designed with the same MR image set and the same structure set for each patient, using the standard opposing lateral beams and fractionation (3 Gy × 10). Physical radiation doses and biologically effective doses (BEDs) in WBRT and SRS were calculated for each lesion target and for the normal brain tissues for comparison of the 2 modalities in the context of clinical efficacy and published toxicities., Results: The BEDs targeted to the tumor were higher in SRS than in WBRT by factors ranging from 2.4- to 3.0- fold for the mean dose and from 3.2- to 5.3-fold for the maximum dose. In the 5 patients, mean BEDs in SRS (calculated as percentages of BEDs in WBRT) were 1.3%-34.3% for normal brain tissue, 0.7%-31.6% for the brainstem, 0.5%-5.7% for the chiasm, 0.2%-5.7% for optic nerves, and 0.6%-18.1% for the hippocampus., Conclusions: The dose-volume metrics presented in this study were essential to understanding the safety and efficacy of WBRT and SRS for multiple brain metastases. Whole-brain radiotherapy results in a higher incidence of radiation-related toxicities than SRS. Even in patients with > 10 brain metastases, the normal CNS tissues receive significantly lower doses in SRS. The mean normal brain dose in SRS correlated with the total volume of the lesions rather than with the number of lesions treated.
- Published
- 2014
- Full Text
- View/download PDF
17. Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer.
- Author
-
Kubicek GJ, Xue J, Xu Q, Asbell SO, Hughes L, Kramer N, Youssef A, Chen Y, Aikens J, Saul H, Pahlajani N, and LaCouture T
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Middle Aged, Radiation Dosage, Radiotherapy Dosage, Retrospective Studies, Treatment Outcome, Brachytherapy methods, Genital Neoplasms, Female therapy, Radiosurgery methods
- Abstract
Introduction: Brachytherapy plays a key role in the treatment of many gynecologic cancers. However, some patients are unable to tolerate brachytherapy for medical or other reasons. For these patients, stereotactic body radiotherapy (SBRT) offers an alternative form of treatment., Methods: Retrospective review of patients prospectively collected on SBRT database is conducted. A total of 11 gynecologic patients who could not have brachytherapy received SBRT for treatment of their malignancies. Five patients have been candidates for interstitial brachytherapy, and six have required tandem and ovoid brachytherapy. Median SBRT dose was 25 Gy in five fractions., Results: At last followup, eight patients were alive, and three patients had died of progressive disease. One patient had a local recurrence. Median followup for surviving patients was 420 days (median followup for all patients was 120 days). Two patients had acute toxicity (G2 dysuria and G2 GI), and one patient had late toxicity (G3 GI, rectal bleeding requiring cauterization)., Conclusions: Our data show acceptable toxicity and outcome for gynecologic patients treated with SBRT who were unable to receive a brachytherapy boost. This treatment modality should be further evaluated in a phase II study.
- Published
- 2013
- Full Text
- View/download PDF
18. Dose-volume effects on brainstem dose tolerance in radiosurgery.
- Author
-
Xue J, Goldman HW, Grimm J, LaCouture T, Chen Y, Hughes L, and Yorke E
- Subjects
- Adult, Aged, Dose Fractionation, Radiation, Dose-Response Relationship, Radiation, Female, Humans, Hyperesthesia etiology, Hypesthesia etiology, Male, Middle Aged, Radiotherapy Dosage, Brain Stem radiation effects, Brain Stem surgery, Radiosurgery adverse effects, Trigeminal Neuralgia surgery
- Abstract
Object: Dose-volume data concerning the brainstem in stereotactic radiosurgery (SRS) for trigeminal neuralgia (TN) were analyzed in relation to associated complications. The authors present their set of data and compare it with currently cited information on brainstem dose tolerance associated with conventional fractionated radiation therapy and hypofractionated radiation treatment of other diseases., Methods: Stereotactic radiosurgery for TN delivers a much higher radiation dose to the brainstem in a single fraction than doses delivered by any other procedures. A literature survey of articles on radiosurgery for TN revealed no incidences of severe toxicity, unlike other high-dose procedures involving the brainstem. Published data on brainstem dose tolerance were investigated and compared with dose-volume data in TN radiosurgery. The authors also performed a biological modeling study of dose-volume data involving the brainstem in cases of TN treated with the Gamma Knife, CyberKnife, and linear accelerator-based systems., Results: The brainstem may receive a maximum dose as high as 45 Gy during radiosurgery for TN. The major complication after TN radiosurgery is mild to moderate facial numbness, and few other severe toxic responses to radiation are observed. The biologically effective dose of 45 Gy in a single fraction is much higher than any brainstem dose tolerance currently cited in conventional fractionation or in single or hypofractionated radiation treatments. However, in TN radiosurgery, the dose falloff is so steep and the delivery so accurate that brainstem volumes of 0.1-0.5 cm(3) or larger receive lower planned and delivered doses than those in other radiation-related procedures. Current models are suggestive, but an extensive analysis of detailed dose-volume clinical data is needed., Conclusions: Patients whose TN is treated with radiosurgery are a valuable population in which to demonstrate the dose-volume effects of an extreme hypofractionated radiation treatment on the brainstem. The result of TN radiosurgery suggests that a very small volume of the brainstem can tolerate a drastically high dose without suffering a severe clinical injury. The authors believe that the steep dose gradient in TN radiosurgery plays a key role in the low toxicity experienced by the brainstem.
- Published
- 2012
- Full Text
- View/download PDF
19. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife.
- Author
-
Xu Q, Chen Y, Grimm J, Fan J, An L, Xue J, Pahlajani N, and Lacouture T
- Subjects
- Breast Neoplasms surgery, Female, Humans, Monte Carlo Method, Phantoms, Imaging, Radiometry, Retrospective Studies, Breast surgery, Mastectomy, Segmental methods, Radiosurgery methods
- Abstract
Purpose: To investigate the dosimetric feasibility of accelerated partial breast irradiation (APBI) using CyberKnife., Methods: Fourteen previously treated patients with early-stage breast cancer were selected for a retrospective study. Six of these patients had been treated to 38.5 Gy in 10 fractions in a phase III accelerated partial breast trial and the rest of the patients were treated to 50.4 Gy in 28 fractions. In this planning study, the guidelines in the protocol for the phase III partial breast trial were followed for organ delineation and CyberKnife planning. The achievable dosimetric parameters from all CyberKnife plans were compared to Intensity-modulated radiation therapy (IMRT) and 3D-CRT methods. The reproducibility of the dose delivery with and without respiratory motion was assessed through delivering a patient plan to a breast phantom. Different dose calculation algorithms were also compared between ray tracing and Monte Carlo., Results: For all the patients in the study, the dosimetric parameters met the guidelines from the NSABP B39∕RTOG 0413 protocol strictly. The mean PTV volume covered by 100% of the prescription dose was 95.7 ± 0.7% (94.7%-97.1%). The mean maximal dose was 104 ± 2% of the prescription dose. The mean V(50%) and mean V(100%) to the ipsilateral normal breast were 23.1 ± 11.6% and 9.0 ± 5.8%, respectively. The conformity index of all plans was 1.14 ± 0.04. The maximum dose to the contralateral breast varied from 1.3 cGy to 111 cGy. The mean V(5%) and mean V(30%) to the contralateral and ipsilateral lungs were 1.0 ± 1.6% and 1.3 ± 1.2%, respectively. In our study, the mean V(5%) to the heart was 0.2 ± 0.5% for right-sided tumors and 9.4 ± 10.1% for left-sided tumors. Compared with IMRT and 3D-CRT planning, the PTV coverage from CyberKnife planning was the highest, and the ratio of V(20%) to V(100%) of the breast from CyberKnife planning was the smallest. The heart and lung doses were similar in all the techniques except that the V(5%) for the lung and heart in CyberKnife planning was slightly higher., Conclusions: The dosimetric feasibility of APBI using CyberKnife was investigated in this retrospective study. All the dosimetric parameters strictly met the guidelines from the NSABP B39∕RTOG 0413 protocol. With advanced real-time tracking capability, CyberKnife should provide better target coverage and spare nearby critical organs for APBI treatment.
- Published
- 2012
- Full Text
- View/download PDF
20. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy.
- Author
-
Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, and Xue J
- Subjects
- Brain Neoplasms radiotherapy, Child, Clinical Trials as Topic, Comorbidity, Dose-Response Relationship, Radiation, Humans, Radiation Tolerance, Radiotherapy Dosage, Time Factors, Tissue Distribution, Radiometry methods, Radiosurgery methods, Radiotherapy Planning, Computer-Assisted methods
- Abstract
Almost 20 years ago, Emami et al. presented a comprehensive set of dose tolerance limits for normal tissue organs to therapeutic radiation, which has proven essential to the field of radiation oncology. The paradigm of stereotactic body radiotherapy (SBRT) has dramatically different dosing schemes but, to date, there has still been no comprehensive set of SBRT normal organ dose tolerance limits. As an initial step toward that goal, we performed an extensive review of the literature to compare dose limits utilized and reported in existing publications. The impact on dose tolerance limits of some key aspects of the methods and materials of the various authors is discussed. We have organized a table of 500 dose tolerance limits of normal structures for SBRT. We still observed several dose limits that are unknown or not validated. Data for SBRT dose tolerance limits are still preliminary and further clinical trials and validation are required. This manuscript presents an extensive collection of normal organ dose tolerance limits to facilitate both clinical application and further research.
- Published
- 2011
- Full Text
- View/download PDF
21. A quality assurance method with submillimeter accuracy for stereotactic linear accelerators.
- Author
-
Grimm J, Grimm SY, Das IJ, Zhu Y, Yeo I, Xue J, Simpson L, Jacob D, and Sarkar A
- Subjects
- Humans, Image Processing, Computer-Assisted, Lasers, Quality Control, Radiosurgery instrumentation, Reproducibility of Results, Sensitivity and Specificity, Radiosurgery methods, Stereotaxic Techniques
- Abstract
The Stereotactic Alignment for Linear Accelerator (S. A. Linac) system is developed to conveniently improve the alignment accuracy of a conventional linac equipped with stereotactic cones. From the Winston-Lutz test, the SAlinac system performs three-dimensional (3D) reconstruction of the quality assurance (QA) ball coordinates with respect to the radiation isocenter, and combines this information with digital images of the laser target to determine the absolute position of the room lasers. A handheld device provides near-real-time repositioning advice to enable the user to align the QA ball and room lasers to within 0.25 mm of the centroid of the radiation isocenter. The results of 37 Winston-Lutz tests over 68 days showed that the median 3D QA ball alignment error was 0.09 mm, and 97% of the time the 3D error was ≤ 0.25 mm. All 3D isocentric errors in the study were 0.3 mm or less. The median x and y laser alignment coordinate error was 0.09 mm, and 94% of the time the x and y laser error was ≤ 0.25 mm. A phantom test showed that the system can make submillimeter end-to-end accuracy achievable, making a conventional linac a "Submillimeter Knife".
- Published
- 2010
- Full Text
- View/download PDF
22. Clinical evidence for dose tolerance of the central nervous system in hypofractionated radiotherapy
- Author
-
Xue, Jinyu, Emami, Bahman, Grimm, Jimm, Kubicek, Gregory J., Asbell, Sucha O., Lanciano, Rachelle, Welsh, James S., Peng, Luke, Quon, Harry, Laub, Wolfram, Gui, Chengcheng, Spoleti, Nicholas, Das, Indra J., Goldman, Howard Warren, Redmond, Kristin J., Kleinberg, Lawrence R., and Brady, Luther W.
- Published
- 2018
- Full Text
- View/download PDF
23. Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models.
- Author
-
Mahadevan, Anand, Emami, Bahman, Grimm, Jimm, Kleinberg, Lawrence R., Redmond, Kristin J., Welsh, James S., Rostock, Robert, Kemmerer, Eric, Forster, Kenneth M., Stanford, Jason, Shah, Sunjay, Asbell, Sucha O., LaCouture, Tamara A., Scofield, Carla, Butterwick, Ian, Xue, Jinyu, Muacevic, Alexander, and Adler, John R.
- Subjects
STEREOTACTIC radiotherapy ,TUMOR treatment ,RESPIRATION ,SMALL intestine ,MOTION ,SUPERIOR mesenteric artery syndrome - Abstract
Objective: To determine the long-term normal tissue complication probability with stereotactic body radiation therapy (SBRT) treatments for targets that move with respiration and its relation with the type of respiratory motion management (tracking vs. compression or gating). Methods: A PubMed search was performed for identifying literature regarding dose, volume, fractionation, and toxicity (grade 3 or higher) for SBRT treatments for tumors which move with respiration. From the identified papers logistic or probit dose-response models were fitted to the data using the maximum-likelihood technique and confidence intervals were based on the profile-likelihood method in the dose-volume histogram (DVH) Evaluator. Results: Pooled logistic and probit models for grade 3 or higher toxicity for aorta, chest wall, duodenum, and small bowel suggest a significant difference when live motion tracking was used for targeting tumors with move with respiration which was on the average 10 times lower, in the high dose range. Conclusion: Live respiratory motion management appears to have a better toxicity outcome when treating targets which move with respiration with very steep peripheral dose gradients. This analysis is however limited by sparsity of rigorous data due to poor reporting in the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Estimated Risk Level of Unified SBRT Dose Tolerance Limits for Spinal Cord
- Author
-
Grimm, Jimm, Sahgal, Arjun, Soltys, Scott G., Luxton, Gary, Patel, Ashish, Herbert, Scott, Xue, Jinyu, Ma, Lijun, Yorke, Ellen, Adler, John R., and Gibbs, Iris C.
- Subjects
Risk ,Spinal Cord ,Humans ,Radiotherapy Dosage ,Radiation Injuries ,Radiosurgery ,Radiation Tolerance ,Article - Abstract
A literature review of more than 200 stereotactic body radiation therapy spine articles from the past 20 years found only a single article that provided dose-volume data and outcomes for each spinal cord of a clinical dataset: the Gibbs 2007 article (Gibbs et al, 2007(1)), which essentially contains the first 100 stereotactic body radiation therapy (SBRT) spine treatments from Stanford University Medical Center. The dataset is modeled and compared in detail to the rest of the literature review, which found 59 dose tolerance limits for the spinal cord in 1-5 fractions. We partitioned these limits into a unified format of high-risk and low-risk dose tolerance limits. To estimate the corresponding risk level of each limit we used the Gibbs 2007 clinical spinal cord dose-volume data for 102 spinal metastases in 74 patients treated by spinal radiosurgery. In all, 50 of the patients were previously irradiated to a median dose of 40Gy in 2-3Gy fractions and 3 patients developed treatment-related myelopathy. These dose-volume data were digitized into the dose-volume histogram (DVH) Evaluator software tool where parameters of the probit dose-response model were fitted using the maximum likelihood approach (Jackson et al, 1995(3)). Based on this limited dataset, for de novo cases the unified low-risk dose tolerance limits yielded an estimated risk of spinal cord injury of ≤1% in 1-5 fractions, and the high-risk limits yielded an estimated risk of ≤3%. The QUANTEC Dmax limits of 13Gy in a single fraction and 20Gy in 3 fractions had less than 1% risk estimated from this dataset, so we consider these among the low-risk limits. In the previously irradiated cohort, the estimated risk levels for 10 and 14Gy maximum cord dose limits in 5 fractions are 0.4% and 0.6%, respectively. Longer follow-up and more patients are required to improve the risk estimates and provide more complete validation.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.